{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:48:28Z","timestamp":1761745708075,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.dsx.2022.102661","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T21:56:52Z","timestamp":1667339812000},"page":"102661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiorenal disease management in type 2 diabetes: An expert consensus"],"prefix":"10.1016","volume":"16","author":[{"given":"Viswanathan","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awadhesh Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Hamid","family":"Zargar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Kumar","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish Chander","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshed","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padhinhare P.","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Jeloka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upendra","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Sakhuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal Kanti","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"IDF diabetes atlas","key":"10.1016\/j.dsx.2022.102661_bib1"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12889-019-6445-6","article-title":"Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort","volume":"19","author":"Vijayakumar","year":"2019","journal-title":"BMC Publ Health"},{"issue":"5","key":"10.1016\/j.dsx.2022.102661_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.hjc.2017.01.003","article-title":"Diabetes and cardiorenal syndrome: understanding the \"triple threat","volume":"58","author":"Banerjee","year":"2017","journal-title":"Hellenic J Cardiol"},{"issue":"8","key":"10.1016\/j.dsx.2022.102661_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2014.07.003","article-title":"Basic science: pathophysiology: the cardiorenal metabolic syndrome","volume":"8","author":"Whaley-Connell","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"17","key":"10.1016\/j.dsx.2022.102661_bib5","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American heart association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfz161","article-title":"Diabetes mellitus: a single cardiorenal syndrome umbrella","volume":"13","author":"Rodr\u00edguez","year":"2019","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.dsx.2022.102661_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrendo.2016.53","article-title":"Diabetes mellitus and its complications in India","volume":"12","author":"Unnikrishnan","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1749-6632.2012.06838.x","article-title":"Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations","volume":"1281","author":"Gujral","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.dsx.2022.102661_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001506","article-title":"Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis \u2013 the INSPIRED STUDY","volume":"8","author":"Anjana","year":"2020","journal-title":"BMJ Open Diabetes Research Care"},{"key":"10.1016\/j.dsx.2022.102661_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13098-017-0225-1","article-title":"Cardiovascular risk assessment in patients with diabetes","volume":"9","author":"Bertoluci","year":"2017","journal-title":"Diabetol Metab Syndrome"},{"issue":"6","key":"10.1016\/j.dsx.2022.102661_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11892-018-1002-8","article-title":"Diabetes in South Asians: phenotype, clinical presentation, and natural history","volume":"18","author":"Unnikrishnan","year":"2018","journal-title":"Curr Diabetes Rep"},{"issue":"2","key":"10.1016\/j.dsx.2022.102661_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ihj.2020.03.010","article-title":"Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: evidence from Indian outpatient setting","volume":"72","author":"Ghosal","year":"2020","journal-title":"Indian Heart J"},{"issue":"2","key":"10.1016\/j.dsx.2022.102661_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.dsx.2022.102661_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/HCO.0000000000000647","article-title":"Predictors of heart failure development in type 2 diabetes: a practical approach","volume":"34","author":"Verma","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.dsx.2022.102661_bib15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diabres.2015.01.011","article-title":"Prediction of heart failure in patients with type 2 diabetes mellitus- a systematic review and meta-analysis","volume":"108","author":"Wang","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.dsx.2022.102661_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.diabres.2010.11.030","article-title":"Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients","volume":"93","author":"Chakraborty","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"issue":"9131","key":"10.1016\/j.dsx.2022.102661_bib19","first-page":"854","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"12","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2022.102661_bib20","article-title":"9. Pharmacologic Approaches to glycemic treatment: Standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102661_bib21","article-title":"A\u00a0consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102661_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13410-020-00819-2","article-title":"RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020","volume":"40","author":"Chawla","year":"2020","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.dsx.2022.102661_bib23","first-page":"845","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis Lancet Diabetes","volume":"7","author":"Neuen","year":"2019","journal-title":"Endocrinol"},{"issue":"11","key":"10.1016\/j.dsx.2022.102661_bib24","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.dsx.2022.102661_bib25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME\u00ae trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"issue":"21","key":"10.1016\/j.dsx.2022.102661_bib26","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.dsx.2022.102661_bib27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.dsx.2022.102661_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2022.102661_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.dsx.2022.102661_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.dsx.2022.102661_bib31","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.dsx.2022.102661_bib32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.dsx.2022.102661_bib33","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2022.102661_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102661_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.dsx.2022.102661_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.dsx.2022.102661_bib37","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jdiacomp.2017.02.001","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure","volume":"31","author":"Kosiborod","year":"2017","journal-title":"J\u00a0Diabet Complicat"},{"issue":"23","key":"10.1016\/j.dsx.2022.102661_bib38","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102661_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"10.1016\/j.dsx.2022.102661_bib40","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.dsx.2022.102661_bib41","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"23","key":"10.1016\/j.dsx.2022.102661_bib42","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2022.102661_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.dsx.2022.102661_bib44","first-page":"891","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.dsx.2022.102661_bib45","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10193","key":"10.1016\/j.dsx.2022.102661_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dsx.2022.102661_bib47","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.dsx.2022.102661_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.dsx.2022.102661_bib49","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102661_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.dsx.2022.102661_bib51","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.dsx.2022.102661_bib52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dsx.2022.102661_bib53","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","author":"Jhund","year":"2020","journal-title":"Circulation"},{"issue":"10193","key":"10.1016\/j.dsx.2022.102661_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:21:00Z","timestamp":1761729660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1871402122002788"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102661","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiorenal disease management in type 2 diabetes: An expert consensus","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of Diabetes India.","name":"copyright","label":"Copyright"}],"article-number":"102661"}}